Cazzullo C L, Sacchetti E, Smeraldi E
Institute of Clinical Psychiatry, University of Milan Medical School, Italy.
Prog Neuropsychopharmacol. 1979;3(1-3):25-38. doi: 10.1016/0364-7722(79)90066-3.
In this paper we discuss the relationship between the psychopathology of depressive behavior and the effectiveness of drugs affecting mood. Particular emphasis is given to the recent contribution of the authors (1975-1977) to the specific items of: 1. non-psychological validation of diagnosis of primary affective disorders 2. predictability of the response to antidepressant drugs 3. factors involved in the effectiveness of long-term lithium treatment. Key words: depression, primary affective disorders, secondary affective disorders, unipolar depression, bipolar depression, N1-methylnicotinamide, 3-methoxy-4-hydroxyphenylglycol, tricyclic antidepressant drugs, lithium prophylaxis, intraerythrocyte/plasma lithium ratio.
Cerebral spinal fluid (CSF); intraerythrocyte/plasma lithium ratio (Li ratio); 3-methoxy-4-hydroxyphenylglycol (MHPG): monoamine oxidase (MAO); morbidity risk (MR); N1-methylnicotinamide (N1-MN); norepinephrine (NE); primary affective disorders (PAD); secondary affective disorders (SAD).
在本文中，我们讨论了抑郁行为的精神病理学与影响情绪的药物疗效之间的关系。特别强调了作者（1975 - 1977年）对以下特定项目的最新贡献：1. 原发性情感障碍诊断的非心理学验证；2. 对抗抑郁药物反应的可预测性；3. 长期锂治疗有效性所涉及的因素。关键词：抑郁症、原发性情感障碍、继发性情感障碍、单相抑郁症、双相抑郁症、N1 - 甲基烟酰胺、3 - 甲氧基 - 4 - 羟基苯乙二醇、三环抗抑郁药、锂预防、红细胞内/血浆锂比率。
脑脊液（CSF）；红细胞内/血浆锂比率（Li比率）；3 - 甲氧基 - 4 - 羟基苯乙二醇（MHPG）；单胺氧化酶（MAO）；发病风险（MR）；N1 - 甲基烟酰胺（N1 - MN）；去甲肾上腺素（NE）；原发性情感障碍（PAD）；继发性情感障碍（SAD）。
